Published in
American Society for Pharmacology and Experimental Therapeutics (ASPET), The Journal of Pharmacology and Experimental Therapeutics, 3(376), p. 358-373, 2021
Links
Tools
Improved inhibitory and ADMET properties of blebbistatin derivatives indicate that blebbistatin scaffold is ideal for drug development targeting myosin-2
Journal article published in 2021 by
Máté Gyimesi 
,
Anna Á. Rauscher,
Sharad Kumar Suthar,
Kamirán Á. Hamow,
Kinga Oravecz,
István Lőrincz,
Zsolt Borhegyi,
Máté T. Déri,
Ádám F. Kiss,
Katalin Monostory,
Pál Tamás Szabó,
Suman Nag,
Ivan Tomasic,
Jacob Krans,
Patrick J. Tierney
and other authors.
,
Anna Á. Rauscher,
Sharad Kumar Suthar,
Kamirán Á. Hamow,
Kinga Oravecz,
István Lőrincz,
Zsolt Borhegyi,
Máté T. Déri,
Ádám F. Kiss,
Katalin Monostory,
Pál Tamás Szabó,
Suman Nag,
Ivan Tomasic,
Jacob Krans,
Patrick J. Tierney
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 